IRCT20180113038331N1招募中2 期
Treatment of castration-resistant metastatic prostate cancer, refractory to routine treatment with Lu177-PSMA
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- Male
入选标准
- •Patients with Hx of metastatic prostate cancer resistant to usual treatment
- •Positive Ga68-PSMA PET/CT scan
排除标准
- •survival less than 4 months
- •GFR less than 40cc/min
- •?Serum creatinin >1.5
- •Urinary tract obstruction
- •Bone marrow suppression (WBC <2500 Plat<80000 Hct<8
研究者
相似试验
进行中（未招募）
1 期
Response evaluation with 68Ga-PSMA PET of metastatic prostate cancer castration resistant patients in treatment with 223RaCl2Patients mCRPC eligible to treatment with 223RaCl2MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10005993Term: Bone metastasesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10036223Term: Positron emission tomographySystem Organ Class: 100000004848MedDRA version: 21.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001395-38-ITAZIENDA USL DELLA VALLE D'AOSTA50
尚未招募
2 期
Targeted a-Therapy in Prostate CancerProstate cancer.Malignant neoplasm of prostateIRCT20210612051548N1Boushehr University of Medical Sciences10
招募中
不适用
Metastatic hormone-sensitive and castration resistant prostate cancer registry: CAPRI 3.0NL-OMON24783Radboud University Medical Center10,000
招募中
Unknown
Prospective observational study of castration-resistant prostate cancer with homologous recombination repair-related gene mutations.D011471prostate cancerJPRN-jRCT1050230026Goto Takayuki400
进行中（未招募）
1 期
STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyProstate CancerEUCTR2004-000193-31-GBniversity College London12,000